Now that Danish pharmaceutical company Novo Nordisk has an approval from the US Food and Drug Administration (FDA) in place, Novo Nordisk is ready to launch the obesity drug Wegovy on the US market in late June.
The company is already present on the obesity market with the drug Saxenda. It expects that the new product, which uses semaglutide as an injection-based treatment, will increase sales and give Novo Nordisk access to this unexploited market.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.